Grard AP Nieuwenhuijzen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Grard AP Nieuwenhuijzen has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- H J T Rutten
Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
7 shared publications - G.J. Creemers
Department of Medical Oncology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
2 shared publications - Ignace Hubertus Johannes Theodorus De Hingh
Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands; Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
2 shared publications - R.G. Orsini
Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
2 shared publications - A.J.G. Maaskant
Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
1 shared publication - Ate van der Gaast
Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands
1 shared publication
Latest Publications
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S115
289. Is multi-modality treatment in elderly patients with locally advanced rectal cancer safe?
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S115
289. Is multi-modality treatment in elderly patients with locally advanced rectal cancer safe?
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S46
97. Intraoperative red blood cell salvage in locally recurrent rectal cancer patients
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S46
97. Intraoperative red blood cell salvage in locally recurrent rectal cancer patients
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S25
41. The influence of delaying surgery for esophageal adenocarcinoma after neoadjuvant chemoradiotherapy on postoperative outcome
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S25
41. The influence of delaying surgery for esophageal adenocarcinoma after neoadjuvant chemoradiotherapy on postoperative outcome
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S19-S20
26. Emergency stoma placement in advanced rectal cancer: A practical guideline
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S19-S20
26. Emergency stoma placement in advanced rectal cancer: A practical guideline
- 1 May 2013
- Vol. 71 (4) , 209-14
The standardised mortality ratio is unreliable for assessing quality of care in rectal cancer.
The standardised mortality ratio (SMR) for rectal or anal cancer was above average in a large tertiary referral centre for locally advanced rectal cancer in the Netherlands. The aim of this study was to investigate whether the increased SMR was indeed related to poor quality of care or whether it could be explained by inadequate adjustment for case-mix factors. Between 2006 and 2008, 381 patients were admitted for rectal or anal cancer. The SMR score of this diagnostic group was 230 (95% CI 140 to 355), corresponding with 20 in-hospital deaths. The hospital dataset was merged with data from the Eindhoven Cancer Registry to obtain more detailed information. Patients admitted for palliative care only accounted for 45% (9/20) of the in-hospital mortality. In contrast to the high SMR, postoperative mortality was low, i.e. 2.6%. The majority of the rectal or anal cancer patients were diagnosed in and referred from another hospital. Referred patients more often had an advanced tumour stage, more often underwent resection and were more frequently treated with chemotherapy and/or radiotherapy than non-referred patients (p<0.01). Postoperative mortality rates for referred and non-referred patients were 2.9% and 1.9%, respectively. The increased SMR appeared to be caused by the admission of patients who received palliative care only. Consequently, the SMR is unreliable for the assessment of quality of care in patients with rectal or anal cancer.
- 1 May 2013
- Vol. 71 (4) , 209-14
The standardised mortality ratio is unreliable for assessing quality of care in rectal cancer.
The standardised mortality ratio (SMR) for rectal or anal cancer was above average in a large tertiary referral centre for locally advanced rectal cancer in the Netherlands. The aim of this study was to investigate whether the increased SMR was indeed related to poor quality of care or whether it could be explained by inadequate adjustment for case-mix factors. Between 2006 and 2008, 381 patients were admitted for rectal or anal cancer. The SMR score of this diagnostic group was 230 (95% CI 140 to 355), corresponding with 20 in-hospital deaths. The hospital dataset was merged with data from the Eindhoven Cancer Registry to obtain more detailed information. Patients admitted for palliative care only accounted for 45% (9/20) of the in-hospital mortality. In contrast to the high SMR, postoperative mortality was low, i.e. 2.6%. The majority of the rectal or anal cancer patients were diagnosed in and referred from another hospital. Referred patients more often had an advanced tumour stage, more often underwent resection and were more frequently treated with chemotherapy and/or radiotherapy than non-referred patients (p<0.01). Postoperative mortality rates for referred and non-referred patients were 2.9% and 1.9%, respectively. The increased SMR appeared to be caused by the admission of patients who received palliative care only. Consequently, the SMR is unreliable for the assessment of quality of care in patients with rectal or anal cancer.
- Open Access
- 12 January 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 7
Acute cholecystitis in high risk surgical patients: percutaneous cholecystostomy versus laparoscopic cholecystectomy (CHOCOLATE trial): Study protocol for a randomized controlled trial
Background: Laparoscopic cholecystectomy in acute calculous cholecystitis in high risk patients can lead to significant morbidity and mortality. Percutaneous cholecystostomy may be an alternative treatment option but the current literature does not provide the surgical community with evidence based advice. Methods/Design: The CHOCOLATE trial is a randomised controlled, parallel-group, superiority multicenter trial. High risk patients, defined as APACHE-II score 7-14, with acute calculous cholecystitis will be randomised to laparoscopic cholecystectomy or percutaneous cholecystostomy. During a two year period 284 patients will be enrolled from 30 high volume teaching hospitals. The primary endpoint is a composite endpoint of major complications within three months following randomization and need for re-intervention and mortality during the follow-up period of one year. Secondary endpoints include all other complications, duration of hospital admission, difficulty of procedures and total costs. Discussion: The CHOCOLATE trial is designed to provide the surgical community with an evidence based guideline in the treatment of acute calculous cholecystitis in high risk patients. Trial Registration: Netherlands Trial Register (NTR): NTR2666
- 12 January 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 7
Open AccessAcute cholecystitis in high risk surgical patients: percutaneous cholecystostomy versus laparoscopic cholecystectomy (CHOCOLATE trial): Study protocol for a randomized controlled trial
Background: Laparoscopic cholecystectomy in acute calculous cholecystitis in high risk patients can lead to significant morbidity and mortality. Percutaneous cholecystostomy may be an alternative treatment option but the current literature does not provide the surgical community with evidence based advice. Methods/Design: The CHOCOLATE trial is a randomised controlled, parallel-group, superiority multicenter trial. High risk patients, defined as APACHE-II score 7-14, with acute calculous cholecystitis will be randomised to laparoscopic cholecystectomy or percutaneous cholecystostomy. During a two year period 284 patients will be enrolled from 30 high volume teaching hospitals. The primary endpoint is a composite endpoint of major complications within three months following randomization and need for re-intervention and mortality during the follow-up period of one year. Secondary endpoints include all other complications, duration of hospital admission, difficulty of procedures and total costs. Discussion: The CHOCOLATE trial is designed to provide the surgical community with an evidence based guideline in the treatment of acute calculous cholecystitis in high risk patients. Trial Registration: Netherlands Trial Register (NTR): NTR2666
- 1 February 2010
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 36 (2) , 164-169
Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed
- 1 February 2010
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 36 (2) , 164-169
Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed
- Open Access
- 31 July 2008
- Published by Springer Nature in BMC Medical Physics
- Vol. 8 (1) , 3
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)
Surgical resection is the preferred treatment of potentially curable esophageal cancer. To improve long term patient outcome, many institutes apply neoadjuvant chemoradiotherapy. In a large proportion of patients no response to chemoradiotherapy is achieved. These patients suffer from toxic and ineffective neoadjuvant treatment, while appropriate surgical therapy is delayed. For this reason a diagnostic test that allows for accurate prediction of tumor response early during chemoradiotherapy is of crucial importance. CT-scan and endoscopic ultrasound have limited accuracy in predicting histopathologic tumor response. Data suggest that metabolic changes in tumor tissue as measured by FDG-PET predict response better. This study aims to compare FDG-PET and CT-scan for the early prediction of non-response to preoperative chemoradiotherapy in patients with potentially curable esophageal cancer.
- 31 July 2008
- Published by Springer Nature in BMC Medical Physics
- Vol. 8 (1) , 3
Open AccessNEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)
Surgical resection is the preferred treatment of potentially curable esophageal cancer. To improve long term patient outcome, many institutes apply neoadjuvant chemoradiotherapy. In a large proportion of patients no response to chemoradiotherapy is achieved. These patients suffer from toxic and ineffective neoadjuvant treatment, while appropriate surgical therapy is delayed. For this reason a diagnostic test that allows for accurate prediction of tumor response early during chemoradiotherapy is of crucial importance. CT-scan and endoscopic ultrasound have limited accuracy in predicting histopathologic tumor response. Data suggest that metabolic changes in tumor tissue as measured by FDG-PET predict response better. This study aims to compare FDG-PET and CT-scan for the early prediction of non-response to preoperative chemoradiotherapy in patients with potentially curable esophageal cancer.